Natalie Berger,Diether Kramer,Michael Schrempf et al.
Natalie Berger et al.
Background: Delirium, defined as an acute, fluctuating disturbance in consciousness, attention and cognition, is a common stroke complication and associated with poor functional outcome. Although resource-intensive preven...
Handwriting, touchscreen dexterity and bradykinesia measures in Parkinson's disease: a feature selection study [0.03%]
帕金森病中的笔迹、触屏灵巧度和运动迟缓的测量：一种特征选择方法研究
Andrea Gardoni,Elisabetta Sarasso,Silvia Basaia et al.
Andrea Gardoni et al.
Introduction: Bradykinesia affects handwriting and smartphone usage in patients with Parkinson's disease (pwPD). Objective: To assess h...
Global burden of motor neuron disease: unraveling socioeconomic disparities, aging dynamics, and divergent future trajectories (1990-2040) [0.03%]
全球运动神经元疾病的疾病负担：揭示社会经济差异、老龄化动态及未来分歧（1990-2040）
Kai Liu,Kun Zhang,Anquan Hu et al.
Kai Liu et al.
Background and objectives: Motor neuron disease (MND) is a progressive neurodegenerative disorder associated with high morbidity and mortality. With global aging, the burden of MND is expected to increase, particularly in...
Clinical integration of brain and cord MRI features improves differential diagnosis of multiple sclerosis [0.03%]
临床整合脑和脊髓MRI特征可改善多发性硬化症的鉴别诊断
Maria A Rocca,Sophia Ratzinger,Paolo Preziosa et al.
Maria A Rocca et al.
Objective: To explore the role of brain and spinal cord MRI features in differentiating patients with suspected central nervous system (CNS) inflammatory diseases. ...
Relapse risk after rituximab discontinuation in neuromyelitis optica spectrum disorders: a multi-center retrospective cohort study [0.03%]
利妥昔单抗停药后视神经脊髓炎谱系病复发风险的多中心回顾性队列研究
Shengfei Hu,Ziyu Liao,Rui Wang et al.
Shengfei Hu et al.
Objective: We aimed to evaluate the association between rituximab (RTX) treatment duration and relapse risk, and explore clinical outcomes following treatment discontinuation in neuromyelitis optica spectrum disorder (NMO...
Multicenter Study
Journal of neurology. 2025 May 10;272(6):387. DOI:10.1007/s00415-025-13125-w 2025
Randomized controlled trials for multiple sclerosis: integrating pathology-driven outcomes to capture therapeutic efficacy [0.03%]
随机对照试验在多发性硬化症中的应用：整合病理驱动的结果以捕捉疗效
Massimo Filippi,Paolo Preziosa,Maria A Rocca
Massimo Filippi
Safety and efficacy of teriflunomide on clinical course, and laboratory findings in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis: a triple-blind study [0.03%]
特氟芙苷对人类T淋巴细胞病毒1型相关脊髓病/热带痉挛性轻偏瘫的临床疗效和安全性：一项三盲研究
Neda Ghadiri Jozan,Zohreh Vahidi,Houshang Rafatpanah et al.
Neda Ghadiri Jozan et al.
Background: HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a chronic inflammatory disease of the central nervous system (CNS). Teriflunomide is an oral agent developed for the treatment of multiple...
Randomized Controlled Trial
Journal of neurology. 2025 May 10;272(6):386. DOI:10.1007/s00415-025-13134-9 2025
Correction: The impact of white matter hyperintensities on short-term outcomes of reperfusion therapy in patients with acute ischemic stroke [0.03%]
纠正：白质高信号对急性缺血性卒中再灌注治疗短期结局的影响
Junying Li,Dan Yang,Rui Song et al.
Junying Li et al.
Published Erratum
Journal of neurology. 2025 May 9;272(6):384. DOI:10.1007/s00415-025-12956-x 2025
Lipoprotein-a and white matter abnormalities: predicting small vessel disease in young patients with ischemic cerebrovascular events [0.03%]
脂蛋白(a)与白质异常：年轻缺血性脑血管事件患者的小血管疾病预测因素
Paola Caruso,Marco Liccari,Gabriele Prandin et al.
Paola Caruso et al.
Introduction: Post-stroke cognitive impairment (PSCI) affects 15-70% of ischemic stroke survivors, with vascular dementia contributing significantly to long-term disability. Lipoprotein(a) [Lp(a)] has emerged as a key ris...
FDA vs. EMA: evaluating donanemab and the global debate on accelerated approvals [0.03%]
FDA与EMA：donanemab的评估及全球加速审批辩论
Prakriti Pokhrel,Aakriti Jindal,Qadeer Ahmed
Prakriti Pokhrel